FDA aims to give full approval to Pfizer vaccine by Labor Day
FDA aims to give full approval to Pfizer vaccine by Labor Day
The Hill
Pfizer
vaccines
COVID-19
FDA
Flag link:
Pfizer, Moderna and Alnylam flag pharma labor shortage in MA—and the people bottleneck doesn't stop there
Pfizer, Moderna and Alnylam flag pharma labor shortage in MA—and the people bottleneck doesn't stop there
Fierce Pharma
Pfizer
Moderna Therapeutics
labor shortage
hirings
drug manufacturing
Massachusetts
Flag link:
Senate subcommittee advances FY2022 FDA funding bill
Senate subcommittee advances FY2022 FDA funding bill
RAPS.org
FDA
legislation
Senate
Flag link:
Amgen splashes $550M and plans to hire hundreds in manufacturing push into the Tarheel State
Amgen splashes $550M and plans to hire hundreds in manufacturing push into the Tarheel State
Fierce Pharma
Amgen
North Carolina
drug manufacturing
Flag link:
Abbott bags FDA okay for AI-based heart imaging software
Abbott bags FDA okay for AI-based heart imaging software
Pharmaforum
Abbott Labs
heart imaging software
FDA
artificial intelligence
Flag link:
'Erratic' FDA and inconsistent drug decisions put doctors off new meds: survey
'Erratic' FDA and inconsistent drug decisions put doctors off new meds: survey
Fierce Pharma
FDA
trust
physicians
drug approvals
Flag link:
‘Some way to go’ before decision on Biogen Alzheimer’s drug, says UnitedHealth
‘Some way to go’ before decision on Biogen Alzheimer’s drug, says UnitedHealth
Biopharma Reporter
Unitedhealth Group
Biogen
Aduhelm
payers
Alzheimer's disease
Flag link:
August 3 2021 - Sanofi agrees to buy U.S. mRNA partner Translate Bio in $3.2 billion deal
Flag link:
Sanofi agrees to buy U.S. mRNA partner Translate Bio in $3.2 billion deal
Sanofi agrees to buy U.S. mRNA partner Translate Bio in $3.2 billion deal
CNBC
Sanofi
M&A
Translate Bio
vaccines
COVID-19
Flag link:
CytoDyn catches SEC, DOJ scrutiny over public claims about COVID-19 drug's viability
CytoDyn catches SEC, DOJ scrutiny over public claims about COVID-19 drug's viability
Fierce Biotech
CytoDyn
FDA
COVID-19
DOJ
SEC
Flag link:
AstraZeneca's launch plan for first-in-class lupus med Saphnelo centers on patient-designed support program
AstraZeneca's launch plan for first-in-class lupus med Saphnelo centers on patient-designed support program
Fierce Pharma
AstraZeneca
drug launches
lupus
Saphnelo
patient advocacy groups
Flag link:
Eli Lilly's COVID-19 antibody sales crater as variants, vaccines take a toll
Eli Lilly's COVID-19 antibody sales crater as variants, vaccines take a toll
Fierce Pharma
Eli Lilly
earnings
COVID-19
antibodies
Flag link:
Vaxart Scores IND For S-Only Oral Tablet COVID-19 Vaccine Candidate
Vaxart Scores IND For S-Only Oral Tablet COVID-19 Vaccine Candidate
BioSpace
Vaxart
FDA
COVID-19
vaccines
oral vaccines
Flag link:
BioIntelliSense lands $45M for remote patient monitoring device
BioIntelliSense lands $45M for remote patient monitoring device
MedCity News
BioIntelliSense
remote patient monitoring
devices
funding
Flag link:
3 Reasons Why Pfizer's and Moderna's Vaccine Revenue Growth Is Just Getting Started
3 Reasons Why Pfizer's and Moderna's Vaccine Revenue Growth Is Just Getting Started
Motley Fool
Pfizer
Moderna Therapeutics
vaccines
COVID-19
Flag link:
Rare disease drugmakers to Congress: Don't gut the accelerated approval pathway
Rare disease drugmakers to Congress: Don't gut the accelerated approval pathway
Endpoints
FDA
Rick Pazdur
accelerated approvals
Biogen
Aduhelm
US Congress
Flag link:
Novartis to launch new Zolgensma trial after FDA lifts restriction
Novartis to launch new Zolgensma trial after FDA lifts restriction
Reuters
Novartis
Zolgensma
clinical trials
SMA
FDA
Flag link:
How the Delta Variant Could Change the World of Coronavirus Vaccine Stocks
How the Delta Variant Could Change the World of Coronavirus Vaccine Stocks
Motley Fool
vaccines
COVID-19
Delta COVID-19 variant
Flag link:
This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine
This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine
Motley Fool
Prizer
clinical trials
COVID-19
BNT162b2
BioNTech
Flag link:
Moderna Bolsters mRNA Oncology Business with Autolus' Proprietary Binders
Moderna Bolsters mRNA Oncology Business with Autolus' Proprietary Binders
BioSpace
Autolus Therapeutics
Moderna Therapeutics
RNA
cancer
Flag link:

Pages